Uncategorized
GenSight Biologics Closes $36 Million Series B Preferred Stock Financing
PARIS--(BUSINESS WIRE)--GenSight Biologics S.A. (GenSight), a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye, and in the future, of the central nervous system, announced that it has completed a Series B preferred stock financing of approximately $36 million. New investors included Fidelity Management & Research Company, Jennison Associates (on behalf of certain clients), Sphera Global HealthCare Fun
